Chemiluminescent immunoassays (CLIAs) offer one of the best solutions for the quantification of low concentrations of specific analytes from a complex mixture for in vitro diagnostic industry. The assay format is similar to enzyme-linked immunoassays, usually based on heterogeneous assays where antibodies or antigens are immobilized on a solid phase but one of the components is conjugated with a chemiluminescent label.
The benefits of CLIAs can be enhanced using magnetic beads as a solid platform which improves the separation of the un-bound reagents and reduces the interferences using a magnetic field.
The CLIA assays based on magnetic beads together with chemiluminescent tagging of immunoreagents are widely used in high throughput automated platforms obtaining an amplified signal and decreasing the matrix interferences. The complexity of these type of immunoassays rely on the optimization of several components and parameters. The critical points are highly related to the type of immunoassay format that best suits the desired specifications, magnetic beads selection and conjugation conditions for magnetic particles and chemiluminescent labelling parameters.
Dr. Anabel Lermo is a Research Scientist with demonstrated experience in the field of In Vitro Diagnostic (IVD), skilled in the design of complex platforms for immunoassay sensing. She holds a PhD in Chemistry (Honoured) from the UAB of Barcelona. Her thesis was focused on the design of biomolecular approaches in electrochemical biosensing devices for alimentary field. She worked as a postdoctoral fellow at Analytical Chemistry Division UAB as a leading researcher of investigation projects for immunoassay development applied to biosensor design in the alimentary and clinical fields. Then, she joined Biokit (a company of the Werfen group) for 7 years, developing chemiluminescent immunoassays for automated platforms in the field of infectious diseases. Her activities were mainly focused on the optimization of key component formulation and analyser assay parameters, transferring the reagent to production, generating all the documentation required for verification, validation and registration of the product in various regulatory agencies (CE, Shonin and CFDA). She currently works at Pragmatic Diagnostics developing new assays where immunometric technologies are integrated with appropriate analytical platforms in a streamlined and efficient manner for IVD industry.